HistoSonics Announces $2.25B Acquisition by Top-Tier Investors

Deal News | Aug 07, 2025 | Early Stage Partners LP

HistoSonics, a leading developer of non-invasive tumor therapy technologies, has announced its acquisition in a $2.25 billion management-led deal by a consortium of prominent private and public investors. The acquisition is set to expedite the global reach of HistoSonics' Edison® Histotripsy System, which represents a breakthrough in tumor therapy through its novel histotripsy platform. Early Stage Partners LP, a notable private equity firm, is involved in facilitating this significant transaction. The strategic acquisition underscores confidence in HistoSonics' innovative approach to medical treatment and aligns with the investors' objectives to advance healthcare technologies on an international scale.

Sectors

Health Technology
Private Equity

Geography

United States – HistoSonics is based in Minneapolis, and the announcement was made there, indicating the primary geographic focus of the company.

Industry

Health Technology – The article is primarily related to the health technology industry, as HistoSonics develops and provides innovative medical devices and treatments for tumor therapy.
Private Equity – The involvement of Early Stage Partners LP and other investors highlights the role of private equity in financing and expanding health tech innovations.

Financials

$2.25 billion – The acquisition deal value for HistoSonics.

Participants

Name	Role	Type	Description
HistoSonics	Target company	Company	A company that develops non-invasive tumor therapy technologies, including the Edison® Histotripsy System.
Early Stage Partners LP	Facilitator	PE Firm	A private equity firm involved in facilitating the acquisition of HistoSonics.
K5 Global	Investor	Company	Part of the consortium of investors acquiring a majority stake in HistoSonics.
Consortium of Top-Tier Investors	Acquirer	Company	A syndicate of globally recognized private and public investors acquiring a majority stake in HistoSonics.